Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Research Article

Genetic Variants Identified from GWAS for Predisposition to Type 2 Diabetes Predict Sulfonylurea Drug Response

Author(s):

Volume 17 , Issue 8 , 2017

Page: [580 - 586] Pages: 7

DOI: 10.2174/1566524018666180222122653

Price: $65

Abstract

Background: Several SNPs were identified through GWAS for their association with type 2 diabetes which has implications to pancreatic β-cell physiology.

Objective: We aimed to study the role of risk alleles of TCF7L2, KCNJ11, CDKN2A, CDKAL1, IGF2BP2, SLC30A8 and KCNQ1 along with pharmacokinetic variants in response to sulfonylureas.

Method: We performed a prospective study on 209 newly diagnosed subjects; treatment naive T2D subjects were recruited. Individuals were started with glibenclamide monotherapy and followed-up for 12 weeks. Genotyping was done, using PCR-RFLP and TETRA-ARMS PCR and confirmed by DNA sequencing.

Results: In univariate regression analysis, KCNJ11 (rs5219) was only the predictor for glibenclamide treatment failure.

Conclusion: The present data suggests a possible role of KCNJ11 gene in altered response to glibenclamide.

Keywords: Sulfonylurea, Glibenclamide, Genome Wide Association Studies (GWAS), Type 2 Diabetes, T-ARMSPCR, KCNJ11 gene.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy